SANDBOX-&-CO
5.10.2022 14:01:50 CEST | Business Wire | Press release
Sandbox & Co, a London-based group operating a network of learning businesses, today announced that it has acquired award-winning UK-based children’s subscription service, toucanBox, which will sit within its newest division, Sandbox Experiences.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221005005015/en/
Virginie Charles-Dear, Founder and CEO of toucanBox, UK-based children’s subscription service, that is now part of Sandbox & Co.’s rapidly expanding portfolio (Photo: Business Wire)
Inspired by Montessori learning and championing STEAM (science, technology, engineering, art, and maths), the newly acquired toucanBox provides fun educational opportunities for children aged 3 to 8 yrs. Through custom boxes posted through the letterbox, on a subscription or buy it now basis, it delivers craft materials and activities that help develop children’s key skills and support their cognitive and language development, fine motor skills and mental wellbeing.
‘We have been big fans of toucanBox and feel it is a perfect complement to our existing range of hands-on educational tools.’ said Bhav Singh, founder and CEO of Sandbox. ‘Creativity-filled fun learning is at the heart of what we do and I can’t wait to start working together on new experiences that will keep our users delighted and entertained.’
toucanBox will be joining the company’s new division, Sandbox Experiences, that currently includes Brazilian children’s book club, Leiturinha. Drawing on his expertise in growing Leiturinha into the largest kids book subscription service in Brazil, Sandbox Experiences’ lead, Guilherme Martins, will be focusing on rolling out new products across new markets, including in the USA and Europe.
‘Our goal is to deliver fun-filled learning opportunities for children aged 0-12 around the world’, said Guilherme Martins, president at Sandbox Experiences. ‘toucanBox is the perfect extension to our existing offering and I look forward to collaborating with the team on delivering even more engaging educational opportunities to help improve learning worldwide.’
‘toucanBox is all about learning through hands-on, fun activities and we are excited to join forces with Sandbox to accelerate our growth and pursue our mission to unleash children’s creativity’, said Virginie Charles-Dear, Founder and CEO of toucanBox. ‘We’re looking forward to expanding our product range further and reaching even more families in Europe and across the world.’
Sandbox has seen rapid growth over the last 5 years, and its current portfolio now consists of 18 brands with a peak monthly audience of 65M+ kids, families, and teachers. Its award-winning properties include Code Kingdoms, online coding courses for kids, Hopster, preschool learning platform, and Spanish companies Edujoy and Tellmewow. The company has been acquisitive and continues to focus on its buy and build strategy.
For logo and images click HERE
About Sandbox & Co – https://sandboxandco.com
Sandbox & Co is a London-based group operating a network of learning businesses providing an unparalleled ecosystem of edutainment products that reaches over 65 million children, their parents, and teachers.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221005005015/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom